FDA Outsourcing Strength Carie Boyd operates as an FDA-registered 503B outsourced compounding facility and a 503A specialty pharmacy, enabling compliant high-volume office-use and patient-use medications nationwide. This positions the company as a reliable partner for hospital networks, clinics, and GPOs seeking scalable, regulatory-compliant outsourcing partners.

Hormone Pellet Leader With a long history in hormone therapies and implantable subcutaneous hormone pellets, plus pioneering automated pellet manufacturing, the company can target endocrinology, urology, OB-GYN clinics with pellet supply and custom compounding services.

National Distribution Edge Nationwide distribution to providers and patients, supported by established logistics (including FedEx). This enables partnerships with multi-state networks, hospitals, and telehealth-enabled practices seeking dependable national sourcing for compounded medications.

Capacity & Quality A relocation to a larger, state-of-the-art facility in 2019 signals scalable manufacturing capacity and ongoing adherence to FDA standards. This supports growth with hospitals, clinics, and GPOs that require consistent quality and supply security.

Digital Marketing Readiness An active digital footprint with Microsoft Advertising and modern web technologies suggests strong potential for targeted BD campaigns. Opportunities exist to deploy lead-gen programs to endocrinology, OB-GYN, hospitals, and clinic networks and to develop partner portals for streamlined sourcing.